885518-53-6

Basic information

• Product Name: 4-BROMO-6-AMINO (1H)INDAZOLE
• Synonyms: 4-BROMO-6-AMINO (1H)INDAZOLE;4-BroMo-1H-indazol-6-aMine;6-Amino-4-bromoindazole
• CAS NO: 885518-53-6
• Molecular Formula: C7H6BrN3
• Molecular Weight: 212.05
• Mol File: 885518-53-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-BROMO-6-AMINO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-6-AMINO (1H)INDAZOLE(885518-53-6)
• EPA Substance Registry System: 4-BROMO-6-AMINO (1H)INDAZOLE(885518-53-6)

Safety Data

• Hazardous Substances Data: 885518-53-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-6-AMINO (1H)INDAZOLE is used as a chemical intermediate for the synthesis of various pharmaceuticals, leveraging its structural features to create new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-6-AMINO (1H)INDAZOLE is utilized as a building block in the development of agrochemicals, contributing to the creation of compounds with pesticidal or herbicidal properties.
Used in Medicinal Chemistry Research:
4-BROMO-6-AMINO (1H)INDAZOLE is employed as a key component in medicinal chemistry research, where it is studied for its potential to target specific biological pathways, aiding in the discovery and design of innovative therapeutic agents.
Used as an Anticancer Agent:
4-BROMO-6-AMINO (1H)INDAZOLE has demonstrated potential as an anticancer agent, showing bioactivity that could be harnessed in the development of treatments for various types of cancer.
Used as an Enzyme and Protein Inhibitor:
4-BROMO-6-AMINO (1H)INDAZOLE has also shown promise as an inhibitor of certain enzymes and proteins, which could be significant in the regulation of biological processes and the treatment of related diseases.
These applications highlight the versatility of 4-BROMO-6-AMINO (1H)INDAZOLE and its importance in the fields of chemistry and medicine.

Upstream product

• 1000342-34-6 C₇H₇BrN₂O₂ 
• 99-55-8 2-methyl-5-nitroaniline 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 1527007-63-1 methyl (4-bromo-1H-indazol-6-yl)carbamate 
• 1527007-62-0 4-bromo-1H-indazole-6-carboxamide 
• 885523-43-3 4-bromo-1H-indazole-6-carboxylic acid 
• 885518-47-8 methyl 4-bromo-1H-indazole-6-carboxylate 
• 223519-11-7 methyl 3-amino-5-bromo-4-methylbenzoate 
• 223519-08-2 methyl 3-bromo-4-methyl-5-nitrobenzoate 
• 34545-20-5 3-bromo-4-methyl-5-nitro-benzoic acid 

Downstream Products

• 885518-97-8 C₇H₄BrIN₂ 

Relevant articles and documents

KRAS G12C Inhibitor and application thereof

The invention discloses a novel KRAS G12C inhibitor, wherein the compound as shown in a formula I, and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compoundas shown in the formula I and the composition thereof di

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

Synthesis of substituted 4-(1H-indol-6-yl)-1H-indazoles as potential PDK1 inhibitors

The development of a preparative route to a series of novel 4-(1H-indol-6-yl)-1H-indazole compounds as potential PDK1 inhibitors is described. The synthetic strategy centres on the late-stage Suzuki cross-coupling of N-unprotected indazole and indole frag